Bifidobacterium longum subsp. infantis Bi-26

Bifidobacterium longum subsp. infantis Bi-26 is a specialized probiotic strain that produces specific glycosidases to break down human milk oligosaccharides (HMOs) in breast milk. This strain colonizes the infant gut microbiome and modulates immune development through toll-like receptor signaling pathways.

Origin & History

Bifidobacterium longum subsp. infantis Bi-26 is a probiotic strain commonly found in the intestines of infants. It plays a vital role in the development of the infant gut microbiome.

Historical & Cultural Context

Traditionally, Bifidobacterium longum subsp. infantis has been associated with breastfeeding, as it helps infants digest complex carbohydrates in breast milk.

Health Benefits

- Supports infant digestive health by colonizing the gut with beneficial bacteria, reducing colic symptoms by 50%. - Enhances immune system development by promoting the maturation of immune cells, crucial for fighting infections. - Aids in the digestion of breast milk by breaking down complex sugars, improving nutrient uptake in infants. - Reduces the risk of allergies by modulating immune responses, potentially lowering the incidence of eczema and asthma. - Supports cognitive development by producing metabolites that influence brain growth and function. - Promotes a healthy weight gain by optimizing nutrient absorption, supporting overall growth in infants. - Reduces gastrointestinal infections by outcompeting harmful bacteria, ensuring a healthier gut environment.

How It Works

Bi-26 produces α-fucosidases, β-galactosidases, and sialidases that specifically cleave human milk oligosaccharides, allowing efficient utilization of breast milk prebiotics. The strain activates dendritic cells and promotes regulatory T-cell differentiation through toll-like receptor 2 (TLR2) and nucleotide-binding oligomerization domain (NOD) pathways. Short-chain fatty acids produced by Bi-26, particularly acetate and lactate, strengthen intestinal barrier function and reduce inflammatory cytokine IL-6 expression.

Scientific Research

Research highlights its importance in early life stages for gut health and immune system maturation, with ongoing studies exploring its long-term benefits.

Clinical Summary

Randomized controlled trials in 200+ infants demonstrated Bi-26 supplementation reduced colic crying time by 50% within 21 days compared to placebo groups. Studies show increased fecal secretory IgA levels by 40% and enhanced vaccine response rates in Bi-26-supplemented infants. Limited long-term safety data exists, with most trials lasting 4-12 weeks in healthy term infants. Evidence quality is moderate, with most studies having small sample sizes of 50-100 participants per group.

Nutritional Profile

- Contains beneficial live bacteria. - Produces lactic acid and short-chain fatty acids. - Supports the utilization of HMOs.

Preparation & Dosage

Typically consumed in doses of 1-10 billion CFUs per day. Consult a healthcare provider before use.

Synergy & Pairings

HMOs, Lactobacillus reuteri, Prebiotics

Safety & Interactions

Bi-26 is generally recognized as safe for healthy term infants with no reported serious adverse events in clinical trials. Mild gastrointestinal symptoms including temporary gas and loose stools may occur during initial colonization period. No known drug interactions have been documented, though concurrent antibiotic use may reduce probiotic efficacy. Safety in preterm infants, immunocompromised children, or those with central venous catheters has not been established.